Laval, Quebec, March 23, 2021 – WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the
American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of
MDX-124 - the company’s proprietary therapeutic antibody.
Respiratory viruses such as SARS-CoV-2 often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm. Analysing cytokine responses from patients has unearthed glaringly important differences in how SARS-CoV-2 affects cytokines compared to other common respiratory viruses.
Medannex Ltd (Edinburgh) this week received multiple awards in recognition of notable successes in
several key areas. The late-stage biopharmaceutical company, developing novel treatments for cancers
and autoimmune diseases, was declared the winner in all three categories in which it was nominated at
Scotland’s Life Sciences Annual Awards.
Laval, Quebec, February 19, 2020 – Altasciences announced today that they have acquired WCCT Global, Inc., an early stage clinical research organization, or CRO, located in Southern California on the U.S.A.’s West Coast. This acquisition will complement Altasciences’ current clinical operations in Montreal, Canada, and Kansas City, U.S.A., while being in close proximity to their Washington State preclinical facility.
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies
A team of Discovery Park scientists researching human neurological and psychiatric health conditions is expanding research opportunities for its Kent-based team in mainland Europe, by opening an additional laboratory in Poland.